8-K Announcements
6Material company update
May 8, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Feb 27, 2026·SEC
CG Oncology, Inc. Common stock(CGON)Earnings, Financials & Key Ratios
CGON•NASDAQ
$69.20
Price updated Jul 7, 2026
AboutCG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.Show more
- Revenue$4M+254.7%
- EBITDA-$189M-65.2%
- Net Income-$161M-82.9%
- EPS (Diluted)-2.08-47.5%
- Gross Margin-15.02%-115.0%
- EBITDA Margin-4686.36%+53.4%
- Operating Margin-4722.13%+53.1%
- Net Margin-3985.02%+48.4%
- ROE-21.67%-13.0%
CGON Price & Volume
CG Oncology, Inc. Common stock (CGON) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Milestone Revenue Growth
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Clinical trial execution failure
Key Thesis Takeaways
- CG Oncology remains in a high-risk, pre-commercial phase where clinical trial execution dictates the firm's valuation trajectory.
- While the company maintains a substantial liquidity buffer, the reliance on lumpy milestone payments and the absence of sustainable commercial revenue create significant uncertainty regarding long-term solvency.
- Investors should monitor the company's ability to transition toward commercialization before the current $57.2M quarterly free cash flow burn exhausts the existing capital base.
Verdict Logic
the company's unsustainable business model, characterized by a negative gross margin of 173.5% in 2026Q1, necessitates further capital raises that will likely continue to dilute existing shareholders.
CGON Growth Metrics
CG Oncology, Inc. Common stock (CGON) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years176.56%
TTM666.01%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-76.91%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-53.95%
Return on Capital
10 Years-29.49%
5 Years-29.49%
3 Years-28.48%
Last Year-25.54%
CGON Recent Earnings
CG Oncology, Inc. Common stock (CGON) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/8 qtrs (25%)●Beat Revenue 4/8 qtrs (80%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.71-22.4%
$0.58
Rev
$1M+139.1%
$453,034
Q1 2026
Feb 27, 2026Metric
Actual
Est
EPS
$0.51+16.4%
$0.61
Rev
$2M+412.9%
$450,538
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.57-2.0%
$0.56
Rev
$2M+2706.4%
$59,364
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$0.54-10.2%
$0.49
Rev
—
$81,620
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.71vs $0.58-22.4% | $1Mvs $453,034+139.1% |
| Q1 2026 | Feb 27, 2026 | $0.51vs $0.61+16.4% | $2Mvs $450,538+412.9% |
| Q4 2025 | Nov 14, 2025 | $0.57vs $0.56-2.0% | $2Mvs $59,364+2706.4% |
| Q3 2025 | Aug 8, 2025 | $0.54vs $0.49-10.2% | —vs $81,620 |
Based on last 8 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for CG Oncology, Inc. Common stock (CGON)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $69.20 | $6.1B | -33.27 | 254.7% | -3985.02% | -21.67% | — | |
| $63.24 | $439.45M | 9.78 | 11.92% | 14.91% | 12.25% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — | |
| $16.15 | $984.9M | -8.83 | -5.55% | -529.67% | -11.85% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — |
Compare CGON vs Peers
CG Oncology, Inc. Common stock (CGON) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CGON SEC Filings & Documents
CG Oncology, Inc. Common stock (CGON) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CGON posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CGON Frequently Asked Questions
CG Oncology, Inc. Common stock (CGON) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is CG Oncology, Inc. Common stock's revenue?
CG Oncology, Inc. Common stock (CGON) reported $5.1M in revenue for fiscal year 2025. This represents a 51% decrease from $10.4M in 2021.
How fast is CG Oncology, Inc. Common stock growing?
CG Oncology, Inc. Common stock (CGON) grew revenue by 254.7% over the past year. This is strong growth.
Is CGON profitable?
CG Oncology, Inc. Common stock (CGON) reported a net loss of $186.7M for fiscal year 2025.
Dividend & Returns
What is CGON's return on equity?
CG Oncology, Inc. Common stock (CGON) has a return on equity (ROE) of -21.7%. Negative ROE indicates the company is unprofitable.
What is CG Oncology, Inc. Common stock's free cash flow?
CG Oncology, Inc. Common stock (CGON) had negative free cash flow of $160.4M in fiscal year 2025, likely due to heavy capital investments.